Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.64 -1.48 (-1.44%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
96 97 Next >
Amazon Web Services Now Offers Generative AI Tools For Businesses, Catches Up With Microsoft Azure, Google Cloud
Amazon is stepping into the generative AI arena with a new product called Bedrock, which offers its Amazon Web Services clients the use of generative AI tools. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation 
Via Benzinga
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
3 Reasons to Buy Merck Stock
This list is by no means exhaustive. 
Via The Motley Fool
Check Out What Whales Are Doing With MRK
Via Benzinga
Why Shares of Iovance Biotherapeutics Jumped Monday
The company's stock rally began on Friday. 
Via The Motley Fool
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in... 
Via Benzinga
With Cancer Immunotherapy Market Set To Grow At Double-Digit CAGR Till 2032, This Company Plans To Ride The Wave Through Treatments For Complex Cancers
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company. 
Via Benzinga
Why Is Seagen Stock Trading Higher Today?
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
Via Benzinga
Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC:  
Via Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
The companies tested a key combination in patients with previously untreated bladder cancer. 
Via Investor's Business Daily
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Promising Preclinical Results From Blood Cancer Propel Oncternal To Buy Rating
HC Wainwright has upgraded Oncternal Therapeutics Inc (NASDAQ: ONCT) to Buy from Neutral with a  
Via Benzinga
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to... 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony. 
Via InvestorPlace
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology... 
Via Benzinga
Why Is Moderna Stock Trading Higher Today?
Moderna Inc (NASDAQ: MRNA) announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials over the next five years. 
Via Benzinga
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. 
Via Benzinga
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners. 
Via InvestorPlace
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.